Nymox Pharmaceutical Corporation
NYMXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.17 | 0.09 | 1.36 |
| FCF Yield | -27.77% | -8.83% | -18.20% | -9.22% |
| EV / EBITDA | -2.18 | -5.32 | -4.20 | -8.50 |
| Quality | ||||
| ROIC | 63.22% | 344.61% | 2,152.75% | -2,637.97% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.58 | 0.46 | 0.79 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 35.94% | 22.00% | 47.03% | 2.23% |
| Safety | ||||
| Net Debt / EBITDA | 0.02 | -0.08 | 0.19 | 0.04 |
| Interest Coverage | -18.95 | -136.89 | -154.70 | -320.62 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.35 |
| Cash Conversion Cycle | -1,501,975.00 | -100,308.64 | -51,617.08 | -37,686.28 |